Clinical studies of advanced glycation end product inhibitors and diabetic kidney disease

被引：61

作者：

Williams M.E. ^{[1
]}

机构：

[1] Joslin Diabetes Center, Harvard Medical Center, Boston, MA 02215

来源：

Current Diabetes Reports | 2004年 / 4卷 / 6期

关键词：

Diabetic Nephropathy; Pyridoxamine; Diabetic Kidney Disease; Glycated Albumin; Advanced Glycation Endproducts;

D O I：

10.1007/s11892-004-0054-0

中图分类号：

学科分类号：

摘要：

Current treatment of the nephropathy complication of diabetes mellitus is suboptimal in halting the progression of the complex disease. Among the irreversible effects of sustained hyperglycemia is the heightened formation of advanced glycation end products (AGEs). The role of AGEs in diabetic nephropathy has been established by years of basic research. This article reports progression through human studies of the few AGE inhibitors that have reached clinical development, including pimagedine, pyridoxamine, and alagebrium. Copyright © 2004 by Current Science Inc.

引用

页码：441 / 446

页数：5

共 47 条

[1]

Locatelli F., Canaud B., Eckardt K.U., Et al., The importance of diabetic nephropathy in current nephrological practice, Nephrol. Dial. Transplant., 8, pp. 716-1725, (2003)

[2]

Gordois A., Scuffham P., Shearer A., Et al., The health rare costs of diabetic nephropathy in the United States and the United Kingdom, J. Diabetes Complications, 18, pp. 18-26, (2004)

[3]

Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes control and Complications Trial, Kidney Int., 47, pp. 1703-1720, (1995)

[4]

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus, N. Engl. J. Med., 329, pp. 977-986, (1993)

[5]

Brenner B.M., Cooper M.E., de Zeeuw D., Et al., Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy, N. Engl. J. Med., 345, pp. 861-869, (2001)

[6]

Lewis E.J., Hunsicker L.G., Bain R.P., Rohde R.D., The effect of angiotensin converting-enzyme inhibition on diabetic nephropathy, N. Engl. J. Med., 329, pp. 1456-1462, (1993)

[7]

Brownlee M., Cerami A., Vlassara H., Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications, N. Engl. J. Med., 318, pp. 1315-1321, (1988)

[8]

Williams M.E., New therapies for advanced glycation end product nephrotoxicity: Current challenges, Am. J. Kidney Dis., 41, 3 SUPPL. 1, (2003)

[9]

Caramori M.L., Mauer M., Diabetes and nephropathy, Curr. Opin. Nephrol. Hypertens., 12, pp. 273-282, (2003)

[10]

Raj D.S.C., Choudhury D., Welbourne T.C., Levi M., Advanced glycation end-products: A nephrologist's perspective, Am. J. Kidney Dis., 35, pp. 365-380, (2000)

← 1 2 3 4 5 →